A KRAS peptide vaccine (NCT04117087, Phase I), and a dendritic cell-based vaccine targeting the KRAS G12C, G12D, G12R, and G12V forms (NCT03592888, Phase I) are also under development for CRC and pancreatic cancer treatment [41]. Here, KRAS is linked to pancreatic neoplasm.